Issued 2026-09-16 at $49.76 · now $49.76 (2026-09-16, +0.0% since)
Based on its own history, a month from the 2026-09-16 close, VZ has typically landed between $45.21 and $54.45 — a range of −9.1% to +9.4% from the issuance price $49.76.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
4,685 overlapping 1 month windows · 2008-01-02 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).
The cone is anchored at the 2026-09-16 issuance close ($49.76) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where VZ has typically landed a month from the 2026-09-16 close of $49.76 — the range is history, not a prediction.
- now $49.76 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $49.85 (+0.2%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $47.9–$51.81
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $45.21–$54.45
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2008-09-10 | −24.1% | −24.1% | +0.0% |
| 2008-09-11 | −21.7% | −24.1% | +0.0% |
| 2008-09-25 | −20.5% | −20.5% | +0.4% |
| 3 best | |||
| 2026-01-28 | +27.2% | +0.0% | +27.2% |
| 2026-01-13 | +26.8% | −0.3% | +26.8% |
| 2008-11-20 | +26.2% | +0.0% | +29.2% |
4,685 overlapping windows · 2008-01-02 – 2026-09-16 · not cherry-picked
Fundamentals iCompany financials — revenue, earnings, margins — from the newest filings shown, each carried with its date.iAs-reported figures and standard ratios from FMP, as of 2026-07-25. Revenue, net income and free cash flow can toggle annual or quarterly; margin, ROE and debt-to-equity are shown by fiscal year. We report the figures and the trend — no target price and no over/under-valued call. More on /methodology.
Fair value — three views iIndependent reference estimates of worth (a cash-flow model, peer multiples, analyst targets), shown as separate views — not a single verdict.
iThree independent estimates of per-share value, each by a different method and each with its own assumptions: a discounted-cash-flow intrinsic value, a peer comparable (the median trailing P/E of 17 sector peers times this company's trailing EPS), and the analyst price-target consensus. They routinely disagree — that gap is the point. We show the three marks and the current price; we do not blend them into a single number or call the stock over- or under-valued. Marks as of the latest capture. More on /methodology.- DCF (intrinsic)$111.67
- Peer P/E × EPS · sector median 16.0× · n=17$65.71
- Analyst target · range $43.00–$58.00$50.00
- Current price · last close 2026-09-16$49.76
Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.
iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~19 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.Up-frequency and average month-over-month return · historical frequency, not a prediction
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-15 | Malady Kyle | director | Sale | 1,100 @ $51.19 | $56K | −1.0% of holding | not yet — horizon still open | not yet — horizon still open | 105,466 | Form 4 · filed 1 day after the trade |
| 2026-09-08 | Malady Kyle | director | Sale | 1,100 @ $49.98 | $55K | −1.0% of holding | not yet — horizon still open | not yet — horizon still open | 106,566 | Form 4 · filed 1 day after the trade |
| 2026-09-01 | Malady Kyle | director | Sale | 1,100 @ $50.50 | $56K | −1.0% of holding | not yet — horizon still open | not yet — horizon still open | 107,666 | Form 4 · filed 1 day after the trade |
| 2026-08-25 | Malady Kyle | director | Sale | 1,100 @ $50.06 | $55K | −1.0% of holding | not yet — horizon still open | not yet — horizon still open | 108,766 | Form 4 · filed 1 day after the trade |
| 2026-08-18 | Malady Kyle | director | Sale | 1,100 @ $48.68 | $54K | −1.0% of holding | not yet — horizon still open | not yet — horizon still open | 109,866 | Form 4 · filed 1 day after the trade |
| 2026-05-29 | Hammock Samantha | officer | Sale | 73,069 @ $47.83 | $3.5M | −81.8% of holding | −10.4% | not yet — horizon still open | 16,221 | Form 4 · filed 4 days after the trade |
| 2026-03-02 | Stillwell Mary-Lee | officer | Sale | 8,569 @ $50.00 | $428K | −16.4% of holding | +5.4% | −9.0% | 43,782 | Form 4 · filed 1 day after the trade |
| 2026-02-24 | Vestberg Hans Erik | director | Sale | 200,000 @ $49.61 | $9.9M | −58.0% of holding | +5.2% | −8.0% | 145,069 | Form 4 · filed 1 day after the trade |
| 2026-02-24 | Vestberg Hans Erik | director | Sale | 12,500 @ $49.61 | $620K | −49.0% of holding | +5.2% | −8.0% | 13,024 | Form 4 · filed 1 day after the trade |
| 2026-02-24 | Vestberg Hans Erik | director | Sale | 12,500 @ $49.61 | $620K | −49.0% of holding | +5.2% | −8.0% | 13,023 | Form 4 · filed 1 day after the trade |
| 2026-02-02 | Russo Joseph J. | officer | Sale | 9,579 @ $44.88 | $430K | −17.9% of holding | +16.2% | −3.0% | 44,045 | Form 4 · filed 1 day after the trade |
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
289 award / exercise / gift records — not counted as purchases
Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.
| Date | Person | Role | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-10 | Villanueva Rodriguez Alfonso | officer | Award / grant | 253 | 7,339 | Form 4 |
| 2026-09-10 | SCHULMAN DANIEL H | director | Award / grant | 187 | 9,409 | Form 4 |
| 2026-09-10 | Skiadas Anthony T | officer | Award / grant | 122 | 147,112 | Form 4 |
| 2026-09-10 | Malady Kyle | director | Award / grant | 122 | 424,384 | Form 4 |
| 2026-09-10 | Venkatesh Vandana | officer | Award / grant | 90 | 58,020 | Form 4 |
| 2026-09-10 | Russo Joseph J. | officer | Award / grant | 77 | 84,951 | Form 4 |
| 2026-09-10 | Stillwell Mary-Lee | officer | Award / grant | 41 | 17,144 | Form 4 |
| 2026-08-27 | SCHULMAN DANIEL H | director | Award / grant | 189 | 9,222 | Form 4 |
| 2026-08-27 | Villanueva Rodriguez Alfonso | officer | Award / grant | 123 | 7,086 | Form 4 |
| 2026-08-27 | Malady Kyle | director | Award / grant | 123 | 424,262 | Form 4 |
| 2026-08-27 | Skiadas Anthony T | officer | Award / grant | 123 | 146,990 | Form 4 |
| 2026-08-27 | Venkatesh Vandana | officer | Award / grant | 91 | 57,930 | Form 4 |
| 2026-08-27 | Russo Joseph J. | officer | Award / grant | 78 | 84,874 | Form 4 |
| 2026-08-27 | Stillwell Mary-Lee | officer | Award / grant | 41 | 17,103 | Form 4 |
| 2026-08-13 | SCHULMAN DANIEL H | director | Award / grant | 193 | 9,034 | Form 4 |
| 2026-08-13 | Villanueva Rodriguez Alfonso | officer | Award / grant | 126 | 6,963 | Form 4 |
| 2026-08-13 | Skiadas Anthony T | officer | Award / grant | 126 | 146,866 | Form 4 |
| 2026-08-13 | Malady Kyle | director | Award / grant | 126 | 424,139 | Form 4 |
| 2026-08-13 | Venkatesh Vandana | officer | Award / grant | 93 | 57,839 | Form 4 |
| 2026-08-13 | Russo Joseph J. | officer | Award / grant | 80 | 84,795 | Form 4 |
| 2026-08-13 | Stillwell Mary-Lee | officer | Award / grant | 42 | 17,061 | Form 4 |
| 2026-07-30 | SCHULMAN DANIEL H | director | Award / grant | 202 | 8,717 | Form 4 |
| 2026-07-30 | Malady Kyle | director | Award / grant | 132 | 417,827 | Form 4 |
| 2026-07-30 | Skiadas Anthony T | officer | Award / grant | 132 | 144,602 | Form 4 |
| 2026-07-30 | Venkatesh Vandana | officer | Award / grant | 97 | 56,907 | Form 4 |
| 2026-07-30 | Russo Joseph J. | officer | Award / grant | 84 | 83,481 | Form 4 |
| 2026-07-30 | Villanueva Rodriguez Alfonso | officer | Award / grant | 79 | 6,739 | Form 4 |
| 2026-07-30 | Stillwell Mary-Lee | officer | Award / grant | 44 | 16,772 | Form 4 |
| 2026-07-16 | SCHULMAN DANIEL H | director | Award / grant | 212 | 8,515 | Form 4 |
| 2026-07-16 | Skiadas Anthony T | officer | Award / grant | 139 | 144,470 | Form 4 |
| 2026-07-16 | Malady Kyle | director | Award / grant | 139 | 417,694 | Form 4 |
| 2026-07-16 | Venkatesh Vandana | officer | Award / grant | 102 | 56,810 | Form 4 |
| 2026-07-16 | Russo Joseph J. | officer | Award / grant | 88 | 83,397 | Form 4 |
| 2026-07-16 | Villanueva Rodriguez Alfonso | officer | Award / grant | 83 | 6,660 | Form 4 |
| 2026-07-16 | Stillwell Mary-Lee | officer | Award / grant | 47 | 16,727 | Form 4 |
| 2026-07-07 | Villanueva Rodriguez Alfonso | officer | Award / grant | 47,754 | 47,754 | Form 4 |
| 2026-07-01 | SCHULMAN DANIEL H | director | Award / grant | 222 | 8,303 | Form 4 |
| 2026-07-01 | Malady Kyle | director | Award / grant | 145 | 417,556 | Form 4 |
| 2026-07-01 | Skiadas Anthony T | officer | Award / grant | 145 | 144,331 | Form 4 |
| 2026-07-01 | Venkatesh Vandana | officer | Award / grant | 106 | 56,708 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures iStock trades disclosed by members of Congress for this company, by the date they were filed.iDisclosures shown as facts. A purchase “cluster” (≥2 members of Congress filing a buy within 90 days) has historically preceded modestly higher forward returns — and it persisted out-of-sample, though it roughly halved after 2021 (see below). A descriptive historical tendency, not a signal to trade and not used in our forecast. See /methodology.
As of 2026-09-16 · point-in-time by filed date
A cluster = ≥2 members of Congress filing a purchase within 90 days. The historical tilt persisted after 2021 but roughly halved (+45 → +32 bp/mo forward 1-month vs the S&P 500 weekly-grid baseline). Descriptive historical tendency — not a signal to trade, and not used in our forecast (audition-log 2026-07-27, recomputed 2026-09-08).
| Member | Chamber | Type | Filed | Traded | Size |
|---|---|---|---|---|---|
| Alan Armstrong | Senate | purchase | 2026-07-21 | 2026-03-27 | $1–15K |
| Ro Khanna | House | sale | 2026-07-06 | 2026-06-30 | $1–15K |
| Ro Khanna | House | sale | 2026-07-06 | 2026-06-02 | $1–15K |
| Ro Khanna | House | purchase | 2026-06-09 | 2026-05-27 | $1–15K |
| Ro Khanna | House | purchase | 2026-06-09 | 2026-05-01 | $1–15K |
| Ro Khanna | House | purchase | 2026-06-09 | 2026-05-15 | $15–50K |
| Gilbert Cisneros | House | purchase | 2026-05-08 | 2026-04-14 | $1–15K |
| Lloyd K. Smucker | House | sale | 2026-04-30 | 2026-04-23 | $1–15K |
| Jennifer Mcclellan | House | sale | 2026-04-16 | 2026-04-07 | $100–250K |
| Pete Sessions | House | sale | 2026-03-09 | 2026-03-09 | $1–15K |
| Sheldon Whitehouse | Senate | sale | 2026-03-06 | 2026-02-23 | $1–15K |
| Ro Khanna | House | purchase | 2026-02-06 | 2026-01-13 | $1–15K |
| Ro Khanna | House | purchase | 2026-02-06 | 2026-01-23 | $1–15K |
| Ro Khanna | House | sale | 2026-02-06 | 2026-01-29 | $1–15K |
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.